Table 3.
Influence of HT on plasma levels of MMP-2, MMP-9, and TIMP-4.
| CAD + HT + DM− | Control | p value | CAD + HT + DM− | CAD + HT − DM− | p value | |
|---|---|---|---|---|---|---|
| MMP-2 (ng/ml) | 133.8 ± 23.4 | 165.7 ± 19.1 | <0.001 | 133.8 ± 23.4 | 134.5 ± 23.2 | 0.93 |
| MMP-9 (ng/ml) | 40.9 ± 23.3 | 47.2 ± 22.3 | 0.40 | 40.9 ± 23.3 | 47.6 ± 29.4 | 0.46 |
| TIMP-4 (pg/ml) | 1573.1 ± 765.6 | 1153.2 ± 339.9 | 0.038 | 1573.1 ± 765.6 | 1733.0 ± 665.4 | 0.55 |
CAD + HT + DM−: group of patients suffering from coronary artery disease and hypertension without diabetes; CAD + HT − DM−: group of patients suffering from coronary artery disease only; MMP-2: matrix metalloproteinase-2; MMP-9: matrix metalloproteinase-9; TIMP-4: tissue inhibitor of metalloproteinases 4. Mean ± SEM. Statistical tests used: Mann–Whitney U test and unpaired t-test.